Report From the NEI/FDA Endpoints Workshop on Age-Related Macular Degeneration and Inherited Retinal Diseases
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
The Association for Research in Vision (ARVO), together with the Foundation Fighting Blindness (FFB), organized the National Eye Institute (NEI)–Food and Drug Administration (FDA) endpoints workshop on age-related macular degeneration (AMD) and inherited retinal diseases (IRD) on November 9, 2016. The public workshop convened basic researchers, clinicians, and regulatory authorities in an interactive forum to discuss the latest clinical findings on AMD and IRD with the goal of optimizing clinical trial design and developing trial endpoints. Specifically, the aim of the workshop was to assemble stakeholders from academic and regulatory spheres to discuss clinical data on potential primary and secondary clinical trial endpoints; patient stratification for disease monitoring, interventions, and evaluation of treatment response; and identification of future research avenues. The workshop was jointly organized by Dr. Frederick Ferris III, MD, Clinical Director at the NEI; Dr. Emily Chew, MD, Deputy Clinical Director at the NEI; Dr. Karl Csaky, MD, PhD, Managing Director and Head of Molecular Ophthalmology Laboratory at the Retina Foundation of the Southwest; Dr. Jacque L. Duncan, MD, Professor of Clinical Ophthalmology at the University of California, San Francisco; and Janet K. Cheetham, PharmD, from the FFB. The workshop format was a series of presentations followed by panel discussions, in which FDA representatives offered regulatory perspectives on potential endpoints for clinical trial design. The following key topics were discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In REFLECT, all eye groups, including placebo eyes, showed a statistically significant and clinically relevant improvement24 in mean LogMAR BCVA at 1.5 years versus nadir, similar to the bilateral response seen in both treated and sham eyes in REVERSE and RESCUE, and to a degree not reported in natural history studies of LHON patients of corresponding age and genotype.18”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [24]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lamoureux, E. L., Pallant, J. F., Pesudovs, K., Hassell, J. B., & Keeffe, J. E. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.06-0220 · Cited by 227 · cited 1×
“Dagnelie discussed a relatively modern mixed PRO, namely, the IVI questionnaire.(14) The content of this questionnaire has been validated by expert panel and focus groups, and it includes three domains: mobility and independence, emotional well-being, and reading and accessing information.”
BackgroundSchmitz-Valckenberg, S., Brinkmann, C. K., Alten, F., Herrmann, P., Stratmann, N. K., Göbel, A. P., Fleckenstein, M., Diller, M., Jaffe, G. J., & Holz, F. G. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.11-7457 · Cited by 201 · cited 1×
“Holz described semiautomated image processing software to detect and quantify such lesions.(1) Dr.”
MethodYehoshua, Z., Wang, F., Rosenfeld, P. J., Penha, F. M., Feuer, W. J., & Gregori, G. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.05.008 · Cited by 190
Visual acuity as an outcome measure in clinical trials of retinal diseases
Beck, R. W., Maguire, M. G., Bressler, N. M., Glassman, A. R., Lindblad, A. S., & Ferris, F. L. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.06.047 · Cited by 188 · cited 1×
“percentage of success or failure between different treatment groups based on a specific number of lines on the scale.(8) Using mean changes requires smaller sample sizes in trials, increases precision, and helps avoid issues of misclassification around a”
BackgroundSelf-citationAbdelfattah, N. S., Zhang, H., Boyer, D. S., Rosenfeld, P. J., Feuer, W. J., Gregori, G., & Sadda, S. R. (2016) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.15-18572 · Cited by 167
Psychometric Properties of the Veterans Affairs Low-Vision Visual Functioning Questionnaire
Stelmack, J. A., Szlyk, J. P., Stelmack, T. R., Demers-Turco, P., Williams, R. T., Moran, D., & Massof, R. W. (2004) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.04-0208 · Cited by 141 · cited 2×
“Dagnelie described a relatively modern Visual Function Questionnaire (VFQ) instrument, namely, the Veterans Administration Low Vision VFQ.(15) Dr.”
MethodRatnam, K., Carroll, J., Porco, T. C., Duncan, J. L., & Roorda, A. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-12557 · Cited by 109 · cited 1×
“Until approximately 50% of the cones were lost, visual acuity appeared to be relatively normal, decreasing below 20/25 after that threshold.(7) These findings suggest that combining AOSLO with other techniques such as SD-OCT, microperimetry, and visual acuity could increase the sensitivity of each technique for imagin…”
BackgroundSelf-citationA short-duration dark adaptation protocol for assessment of age-related maculopathy
Jackson, G. R., & Edwards, J. G. (2008) · Journal of Ocular Biology, Diseases, and Informatics · doi:10.1007/s12177-008-9002-6 · Cited by 108 · cited 1×
“Catherine Cukras discussed details of a study on dark adaptation in patients with various stages of AMD using a prototype of the AdaptDx device, which delivers an 80% focal bleach to a circular test spot on the retina located at 58 on the inferior visual meridian.(9) The study revealed that dark adaptation time tended…”
MethodLow-Luminance Visual Acuity and Microperimetry in Age-Related Macular Degeneration
Wu, Z., Ayton, L. N., Guymer, R. H., & Luu, C. D. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.02.005 · Cited by 106 · cited 1×
“3 letters in one study.(10) Independent analysis by different groups suggests that LLD measurements are reproducible and precise, as indicated by test–retest variability.”
BackgroundEye Tracking in the Wild: the Good, the Bad and the Ugly
Lappi, O. (2015) · Journal of Eye Movement Research · doi:10.16910/jemr.8.5.1 · Cited by 90 · cited 1×
“For example, stimuli in naturalistic tests are often rich and complex and include unlimited fields of view; tasks are often learned well before the experiment and embedded within natural behavior; and the behaviors entail unrestricted head and body movements and complex sequential actions.(13) Dr.”
Background
Cited by
Age-related macular degeneration
Fleckenstein, M., Keenan, T. D. L., Guymer, R. H., Chakravarthy, U., Schmitz-Valckenberg, S., Klaver, C. C., Wong, W. T., & Chew, E. Y. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00265-2 · Cited by 978
Self-citationC5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration
Jaffe, G. J., Westby, K., Csaky, K. G., Monés, J., Pearlman, J. A., Patel, S. S., Joondeph, B. C., Randolph, J., Masonson, H., & Rezaei, K. A. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2020.08.027 · Cited by 469
Self-citationBrennan, N. A., Toubouti, Y. M., Cheng, X., & Bullimore, M. A. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100923 · Cited by 355
“The FDA CDER has shown a clear preference for functional over anatomic endpoints for drug and biologic approvals (Csaky et al., 2017).”
Incomplete Retinal Pigment Epithelial and Outer Retinal Atrophy in Age-Related Macular Degeneration
Guymer, R. H., Rosenfeld, P. J., Curcio, C. A., Holz, F. G., Staurenghi, G., Freund, K. B., Schmitz-Valckenberg, S., Sparrow, J., Spaide, R. F., Tufail, A., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.09.035 · Cited by 316
Self-citationInherited Retinal Degenerations: Current Landscape and Knowledge Gaps
Duncan, J. L., Pierce, E. A., Laster, A. M., Daiger, S. P., Birch, D. G., Ash, J. D., Iannaccone, A., Flannery, J. G., Sahel, J. A., Zack, D. J., et al. (2018) · Translational Vision Science & Technology · doi:10.1167/tvst.7.4.6 · Cited by 257
“The objective, quantitative, and highresolution nature of OCT measures combined with correlation to functional measures has created interest in using the EZ area as a potential clinical trial outcome measure.(41) In addition, swept-source OCT penetrates deeper into the choroid to facilitate optical coherence tomograph…”
MethodSelf-citationProgression of Geographic Atrophy in Age-related Macular Degeneration
Keenan, T. D., Agrón, E., Domalpally, A., Clemons, T. E., van Asten, F., Wong, W. T., Danis, R. G., Sadda, S., Rosenfeld, P. J., Klein, M. L., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.05.028 · Cited by 219
Self-citationFundus-controlled perimetry (microperimetry): Application as outcome measure in clinical trials
Pfau, M., Jolly, J. K., Wu, Z., Denniss, J., Lad, E. M., Guymer, R. H., Fleckenstein, M., Holz, F. G., & Schmitz-Valckenberg, S. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100907 · Cited by 165
“Regulatory agencies have stated their preference for functional outcome measures that relate to orientation and mobility, daily living in patients' home environments, and occupational needs such as reading (Csaky et al., 2017; Jolly et al., 2019).”
BackgroundEmixustat Hydrochloride for Geographic Atrophy Secondary to Age-Related Macular Degeneration
Rosenfeld, P. J., Dugel, P. U., Holz, F. G., Heier, J. S., Pearlman, J. A., Novack, R. L., Csaky, K. G., Koester, J. M., Gregory, J. K., & Kubota, R. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.03.059 · Cited by 132
Self-citationRiedl, S., Vogl, W., Mai, J., Reiter, G. S., Lachinov, D., Grechenig, C., McKeown, A. S., Scheibler, L., Bogunović, H., & Schmidt-Erfurth, U. M. (2022) · Ophthalmology Retina · doi:10.1016/j.oret.2022.05.030 · Cited by 113
Rojas, J. C., Wang, P., Staffaroni, A. M., Heller, C., Cobigo, Y., Wolf, A., Goh, S.-Y. M., Ljubenkov, P. A., Heuer, H. W., Fong, J. C., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011848 · Cited by 106
“Such an approach was previously used for drugs to treat macular degeneration that were approved for marketing by using optical coherence tomography measurements as endpoints that are highly predictive of future declines in visual acuity.(40)”
MethodKeenan, T. D. L., Agrón, E., Keane, P. A., Domalpally, A., & Chew, E. Y. (2024) · Ophthalmology · doi:10.1016/j.ophtha.2024.07.014 · Cited by 105
Self-citationDrug Approval for the Treatment of Geographic Atrophy: How We Got Here and Where We Need to Go
Csaky, K. G., Miller, J. M. L., Martín, D., & Johnson, M. W. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.02.021 · Cited by 109
Self-citationThompson, D. A., Iannaccone, A., Ali, R. R., Arshavsky, V. Y., Audo, I. S., Bainbridge, J. W., Besirli, C. G., Birch, D. G., Branham, K. E. H., Cideciyan, A. V., et al. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.7.2 · Cited by 99
Self-citationClinical Perspectives and Trends: Microperimetry as a Trial Endpoint in Retinal Disease
Yang, Y., & Dunbar, H. (2021) · Ophthalmologica · doi:10.1159/000515148 · Cited by 96
Zhang, G., Fu, D. J., Liefers, B. J., Faes, L., Glinton, S. L., Wagner, S. K., Struyven, R., Pontikos, N., Keane, P. A., & Balaskas, K. (2021) · The Lancet Digital Health · doi:10.1016/s2589-7500(21)00134-5 · Cited by 95
Endpoints for clinical trials in ophthalmology
Schmetterer, L. F., Scholl, H. P. N., Garhöfer, G., Janeschitz‐Kriegl, L., Corvi, F., Sadda, S. R., & Medeiros, F. A. (2023) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101160 · Cited by 96
“However, high test-retest variability might indicate the need for improvement and testing of different protocols (Csaky et al., 2017; Montesano et al., 2021a).”
BackgroundMethodInfluentialRelationship Between Acuity and Contrast Sensitivity: Differences Due to Eye Disease
Xiong, Y.-Z., Kwon, M., Bittner, A. K., Virgili, G., Giacomelli, G., & Legge, G. E. (2020) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.61.6.40 · Cited by 99
Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy
Newman, N. J., Yu-Wai-Man, P., Subramanian, P. S., Moster, M. L., Wang, A.-G., Donahue, S. P., Leroy, B. P., Carelli, V., Biousse, V., Vignal-Clermont, C., et al. (2023) · Brain · doi:10.1093/brain/awac421 · Cited by 87
Pfau, M., von der Emde, L. A., Dysli, C., Möller, P. T., Thiele, S., Lindner, M., Schmid, M. C., Rubin, D. L., Fleckenstein, M., Holz, F. G., et al. (2020) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2020.04.003 · Cited by 80
“Regulatory agencies including the US Food and Drug Administration have expressed a clear preference for functional over structural endpoints for AMD and inherited retinal diseases.(24) However, conventional functional outcome measures such as BCVA are suboptimal in the context of GA, particularly for patients with fov…”
BackgroundCurcio, C. A., McGwin, G., Sadda, S. R., Hu, Z. J., Clark, M. E., Sloan, K. R., Swain, T. A., Crosson, J. N., & Owsley, C. J. (2020) · BMC Ophthalmology · doi:10.1186/s12886-020-01467-0 · Cited by 75
Reiter, G. S., Told, R., Schranz, M. W., Baumann, L., Mylonas, G., Sacu, S., Pollreisz, A., & Schmidt-Erfurth, U. M. (2020) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.61.6.11 · Cited by 73
Wynne, N., Carroll, J., & Duncan, J. L. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100920 · Cited by 71
Self-citationVingopoulos, F., Wai, K. M., Katz, R., Vavvas, D. G., Kim, L. A., & Miller, J. B. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132768 · Cited by 70
“With the advent of the qCSF, contrast sensitivity can now be efficiently measured across multiple spatial frequencies with both high sensitivity in detecting subtle changes in visual function and great test–retest reliability, fulfilling the FDA criteria for functional endpoints [81,82] and emerging as a promising vis…”
BackgroundMethodLane, J., Rohan, E. M. F., Sabeti, F., Essex, R. W., Maddess, T., Dawel, A., Robbins, R. A., Barnes, N. M., He, X., & McKone, E. (2018) · PLoS ONE · doi:10.1371/journal.pone.0209218 · Cited by 69
Kuppermann, B. D., Patel, S. S., Boyer, D. S., Augustin, A. J., Freeman, W. R., Kerr, K. J., Guo, Q., Schneider, S., López, F. J., & on behalf of the Brimo DDS Gen 1 Study Group (2020) · Retina · doi:10.1097/iae.0000000000002789 · Cited by 72
Nittala, M. G., Metlapally, R., Ip, M. S., Chakravarthy, U., Holz, F. G., Staurenghi, G., Waheed, N. K., Velaga, S. B., Lindenberg, S., Karamat, A., et al. (2022) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2021.6067 · Cited by 68
Newman, N. J., Yu-Wai-Man, P., Carelli, V., Biousse, V., Moster, M. L., Vignal-Clermont, C., Sergott, R. C., Klopstock, T., Sadun, A. A., Girmens, J.-F., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.662838 · Cited by 64
Guymer, R. H., & Wu, Z. (2020) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.13837 · Cited by 67
“In 2017 however, the United States Food and Drug Administration (FDA) suggested that preventing photoreceptor loss would be considered a clinically meaningful trial endpoint given the established link between photoreceptor loss and visual function.(14) Since evidence suggests that nGA is a strong predictor for the dev…”
BackgroundSchmidt-Erfurth, U. M., Mai, J., Reiter, G. S., Riedl, S., Vogl, W., Sadeghipour, A., McKeown, A. S., Foos, E., Scheibler, L., & Bogunović, H. (2024) · Ophthalmology · doi:10.1016/j.ophtha.2024.08.017 · Cited by 63
The Border of Macular Atrophy in Age-Related Macular Degeneration: A Clinicopathologic Correlation
Dolz‐Marco, R., Balaratnasingam, C., Messinger, J. D., Li, M., Ferrara, D., Freund, K. B., & Curcio, C. A. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.06.020 · Cited by 64
Contrast sensitivity function in patients with macular disease and good visual acuity
Wai, K. M., Vingopoulos, F., Garg, I., Kasetty, M. A., Silverman, R. F., Katz, R., Laíns, I., Miller, J. W., Husain, D., Vavvas, D. G., et al. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-318494 · Cited by 59
Determinants of Quality of Life in Geographic Atrophy Secondary to Age-Related Macular Degeneration
Künzel, S. H., Möller, P. T., Lindner, M., Goerdt, L., Nadal, J., Schmid, M. C., Schmitz-Valckenberg, S., Holz, F. G., Fleckenstein, M., & Pfau, M. (2020) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.61.5.63 · Cited by 58
Biomarkers for the Progression of Intermediate Age-Related Macular Degeneration
Lad, E. M., Finger, R. P., & Guymer, R. H. (2023) · Ophthalmology and Therapy · doi:10.1007/s40123-023-00807-9 · Cited by 57
“However, the structural biomarkers used as endpoints in current clinical trials of AMD (presence and/or growth of exudation or atrophy [16, 17]) are associated with late stages of the disease when photoreceptor death and loss of best-corrected visual acuity (BCVA) have already occurred.”
BackgroundChallenges Associated With Ellipsoid Zone Intensity Measurements Using Optical Coherence Tomography
Lee, K. E., Heitkotter, H., & Carroll, J. (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.12.27 · Cited by 51
Ou, W. C., Lesmes, L. A., Christie, A. H., Denlar, R. A., & Csaky, K. G. (2021) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2021.01.017 · Cited by 51
Self-citationFu, D. J., Faes, L., Wagner, S. K., Moraes, G., Chopra, R., Patel, P. J., Balaskas, K., Keenan, T. D. L., Bachmann, L. M., & Keane, P. A. (2021) · Ophthalmology Retina · doi:10.1016/j.oret.2021.01.009 · Cited by 50
Therapy with voretigene neparvovec. How to measure success?
Stingl, K., Kempf, M., Jung, R., Kortüm, F., Righetti, G., Reith, M., Dimopoulos, S., Ott, S., Kohl, S., & Stingl, K. (2023) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101115 · Cited by 48
“(BCVA), although its true importance as a treatment outcome in IRD is low and has been a subject of discussion in recent years (Csaky et al., 2017).”
BackgroundIncomplete Retinal Pigment Epithelial and Outer Retinal Atrophy
Wu, Z., Goh, K. L., Hodgson, L., & Guymer, R. H. (2022) · Ophthalmology · doi:10.1016/j.ophtha.2022.09.004 · Cited by 47
Quantification of Geographic Atrophy Using Spectral Domain OCT in Age-Related Macular Degeneration
Cleland, S. C., Konda, S. M., Danis, R. P., Huang, Y., Myers, D. J., Blodi, B. A., & Domalpally, A. (2020) · Ophthalmology Retina · doi:10.1016/j.oret.2020.07.006 · Cited by 46
Reticular Pseudodrusen Status, ARMS2/HTRA1 Genotype, and Geographic Atrophy Enlargement
Agrón, E., Domalpally, A., Cukras, C. A., Clemons, T. E., Chen, Q., Swaroop, A., Lu, Z., Chew, E. Y., & Keenan, T. D. L. (2022) · Ophthalmology · doi:10.1016/j.ophtha.2022.11.026 · Cited by 46
Self-citationEhlers, J. P., Hu, A. Y. H., Boyer, D. S., Cousins, S. W., Waheed, N. K., Rosenfeld, P. J., Brown, D. M., Kaiser, P. K., Abbruscato, A., Gao, G., et al. (2024) · Ophthalmology Science · doi:10.1016/j.xops.2024.100628 · Cited by 45
“40 The assessment of EZ attenuation as a marker of photoreceptor loss/dysfunction and a predictor of future GA progression has been well established across many diseases, including a link to visual function.”
Terheyden, J. H., Holz, F. G., Schmitz-Valckenberg, S., Lüning, A., Schmid, M. C., Rubin, G. S., Dunbar, H., Tufail, A., Crabb, D. P., Binns, A. M., et al. (2020) · Trials · doi:10.1186/s13063-020-04595-6 · Cited by 44
Chu, Z., Shi, Y., Zhou, X., Wang, L., Zhou, H., Laiginhas, R., Zhang, Q., Cheng, Y., Shen, M., de Sisternes, L., et al. (2021) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2021.10.032 · Cited by 43
Ervin, A., Strauss, R. W., Ahmed, M. I., Birch, D. G., Cheetham, J. K., Ferris, F. L., Ip, M. S., Jaffe, G. J., Maguire, M. G., Schönbach, E. M., et al. (2019) · Translational Vision Science & Technology · doi:10.1167/tvst.8.2.16 · Cited by 41
“During 2016 National Eye Institute (NEI) and FDA symposium on inherited retinal diseases a speaker from the FDA noted a strong preference for functional over anatomic endpoints and for outcomes that are clinically significant.(33)”
BackgroundSelf-citationClinical and preclinical therapeutic outcome metrics for USH2A-related disease
Toms, M., Dubis, A. M., de Vrieze, E., Tracey‐White, D., Mitsios, A., Hayes, M. J., Broekman, S., Baxendale, S., Utoomprurkporn, N., Bamiou, D., et al. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa004 · Cited by 41
“Our choice of EZ and hyperAF rings follows recent changes in Food and Drug Administration (FDA) efficacy evaluation (23).”
BackgroundThe Development and Clinical Application of Innovative Optical Ophthalmic Imaging Techniques
Alexopoulos, P., Madu, C. T., Wollstein, G., & Schuman, J. S. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.891369 · Cited by 51
“As an example, AOSLO can detect cell destruction in retinal degenerations before the onset of symptoms, which would allow the formation of therapeutic clinical trials, while vision is still salvageable in these patients (280, 320).”
BackgroundSyndromic retinitis pigmentosa.
Karuntu, J. S., Almushattat, H., Nguyen, X.-T.-A., Plomp, A. S., Wanders, R. J. A., Hoyng, C. B., van Schooneveld, M. J., Schalij-Delfos, N. E., Brands, M. M., Leroy, B. P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101324 · Cited by 39
Pegcetacoplan Treatment and Consensus Features of Geographic Atrophy Over 24 Months
Fu, D. J., Bagga, P., Naik, G., Glinton, S. L., Faes, L., Liefers, B. J., Lima, R., Wignall, G., Keane, P. A., Ioannidou, E., et al. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.1269 · Cited by 39
Five-Year Outcomes of Lenadogene Nolparvovec Gene Therapy in Leber Hereditary Optic Neuropathy
Yu‐Wai‐Man, P., Newman, N. J., Biousse, V., Carelli, V., Moster, M. L., Vignal‐Clermont, C., Klopstock, T., Sadun, A. A., Sergott, R. C., Hage, R., et al. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.5375 · Cited by 41
Complement inhibitors for age-related macular degeneration
Tzoumas, N., Riding, G., Williams, M. A., & Steel, D. H. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009300.pub3 · Cited by 38
Tee, J. J. L., Yang, Y., Kalitzeos, A. A., Webster, A., Bainbridge, J. W., Weleber, R. G., & Michaelides, M. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-23739 · Cited by 38
Künzel, S. H., Lindner, M., Sassen, J., Möller, P. T., Goerdt, L., Schmid, M. C., Schmitz-Valckenberg, S., Holz, F. G., Fleckenstein, M., & Pfau, M. (2021) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2021.3826 · Cited by 38
Discovering the Potential of Natural Antioxidants in Age-Related Macular Degeneration: A Review
Wong, K.-H., Nam, H.-Y., Lew, S. Y., Naidu, M. K., David, P. R., Kamalden, T. A., Hadie, S. N. H., & Lim, L. W. (2022) · Pharmaceuticals · doi:10.3390/ph15010101 · Cited by 40
Retinal Dystrophies and the Road to Treatment: Clinical Requirements and Considerations
Talib, M., & Boon, C. J. F. (2020) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000290 · Cited by 41
Levin, L. A., Patrick, C., Choudry, N. B., Sharif, N. A., & Goldberg, J. L. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.964197 · Cited by 40
“Many of these considerations and themes have also been described elsewhere (17, 51, 56, 65, 66, 83, 131).”
BackgroundMai, J., Lachinov, D., Riedl, S., Reiter, G. S., Vogl, W., Bogunović, H., & Schmidt-Erfurth, U. M. (2023) · Scientific Reports · doi:10.1038/s41598-023-34139-2 · Cited by 37
“In particular, the regulatory authorities such as the U.S. Food and Drug Administration (FDA) have documented their interest in considering anatomical endpoints when functional parameters are too variable 26 .”
Topical Brimonidine or Intravitreal BDNF, CNTF, or bFGF Protect Cones Against Phototoxicity
Valiente‐Soriano, F. J., Ortín-Martínez, A., Pierdomenico, J. D., García‐Ayuso, D., Gallego‐Ortega, A., de Imperial‐Ollero, J. A. M., Jiménez-López, M., Villegas‐Pérez, M. P., Wheeler, L. A., & Vidal‐Sanz, M. (2019) · Translational Vision Science & Technology · doi:10.1167/tvst.8.6.36 · Cited by 36
Night vision restored in days after decades of congenital blindness
Jacobson, S. G., Cideciyan, A. V., Ho, A. C., Román, A. J., Wu, V. F., Garafalo, A. V., Sumaroka, A., Krishnan, A. K., Świder, M., Mascio, A. A., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105274 · Cited by 38
“The emphasis by the FDA on improvement (by 3 ETDRS lines) of best-corrected visual acuity as a clinically meaningful efficacy endpoint also tended to weigh in favor of cones (Csaky et al., 2017).”
Update on Clinical Trial Endpoints in Gene Therapy Trials for Inherited Retinal Diseases
Igoe, J., Lam, B. L., & Gregori, N. Z. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13185512 · Cited by 35
“Due to the importance of these measures to the validity of the trial, the FDA provides general guidance on endpoint selection [55–57], as well as periodic specialty-specific guidance [58,59].”
BackgroundAdherence to a Mediterranean Diet and Geographic Atrophy Enlargement Rate
Agrón, E., Mares, J. A., Chew, E. Y., & Keenan, T. D. L. (2022) · Ophthalmology Retina · doi:10.1016/j.oret.2022.03.022 · Cited by 36
Self-citationBalaskas, K., Glinton, S. L., Keenan, T. D. L., Faes, L., Liefers, B. J., Zhang, G., Pontikos, N., Struyven, R., Wagner, S. K., McKeown, A. S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-19413-z · Cited by 32
Fasih‐Ahmad, S., Wang, Z., Mishra, Z., Vatanatham, C., Clark, M. E., Swain, T. A., Curcio, C. A., Owsley, C. J., Sadda, S. R., & Hu, Z. J. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.2.1 · Cited by 31
“7 Optical coherence tomography (OCT) is currently used to visualize 3D changes in retinal structure.”
MethodOutcome measures in juvenile X-linked retinoschisis: A systematic review
Grigg, J., Hooper, C., Fraser, C. L., Cornish, E. E., McCluskey, P., & Jamieson, R. V. (2020) · Eye · doi:10.1038/s41433-020-0848-6 · Cited by 31
Strauss, R. W., Ho, A., Jha, A., Fujinami, K., Michaelides, M., Cideciyan, A. V., Audo, I. S., Birch, D. G., Sadda, S. R., Ip, M. S., et al. (2023) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2023.02.003 · Cited by 31
Wu, Z., Hadoux, X., Jannaud, M., Glover, E. K., Gee, E. E., Hodgson, L., van Wijngaarden, P., & Guymer, R. H. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.1.36 · Cited by 30
“38 Our findings suggest that defect-mapping microperimetry testing would be a useful approach for capturing treatments effects on preserving visual function.”
BackgroundKeenan, T. D. L., Vitale, S., Agrón, E., Domalpally, A., Antoszyk, A. N., Elman, M. J., Clemons, T. E., & Chew, E. Y. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.06.001 · Cited by 32
Self-citationA review of treatment modalities in gyrate atrophy of the choroid and retina (GACR)
Balfoort, B. M., Buijs, M. J. N., ten Asbroek, A. L. M. A., Bergen, A. A. B., Boon, C. J. F., Ferreira, E. A., Houtkooper, R. H., Wagenmakers, M. A. E. M., Wanders, R. J. A., Waterham, H. R., et al. (2021) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2021.07.010 · Cited by 35
Carelli, V., Newman, N. J., Yu‐Wai‐Man, P., Biousse, V., Moster, M. L., Subramanian, P. S., Vignal‐Clermont, C., Wang, A.-G., Donahue, S. P., Leroy, B. P., et al. (2022) · Ophthalmology and Therapy · doi:10.1007/s40123-022-00611-x · Cited by 30
“Mean differences at month 18 [15; 21], month 24 [21; 30], month 36 [30; 42] and month 48 [42; 54] were estimated by a mixed-model ANCOVA with repeated measures: *P = 0.”
MethodVingopoulos, F., Bannerman, A., Zhou, P., Koch, T., Wescott, H. E., Kim, L. A., Vavvas, D. G., Miller, J. W., & Miller, J. B. (2023) · British Journal of Ophthalmology · doi:10.1136/bjo-2023-323507 · Cited by 29
“22 As an increasing importance is being placed by regulators on patient-reported outcomes in AMD, from a regulatory perspective, it is an essential prerequisite for any functional test to show a strong relationship with VRQoL.”
BackgroundPolidoro, F. (2020) · Strategic Management Journal · doi:10.1002/smj.3196 · Cited by 33
Boyer, D. S., González, V. H., Kunimoto, D. Y., Maturi, R. K., Roe, R. H., Singer, M. A., Xavier, S., Kornfield, J. A., Kuppermann, B. D., Quiroz–Mercado, H., et al. (2021) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20210528-05 · Cited by 28
Looking Ahead: Visual and Anatomical Endpoints in Future Trials of Diabetic Macular Ischemia
Cheung, C. M. G., Pearce, E., Fenner, B. J., Sen, P., Chong, V. N., & Sivaprasad, S. (2021) · Ophthalmologica · doi:10.1159/000515406 · Cited by 30
Sharma, S., Gupta, V., Maiti, A., Natesh, S., Saxena, S., Dave, V. P., Parmar, V., Sampangi, R., Murthy, H., Dharwadkar, S., et al. (2021) · International Journal of Retina and Vitreous · doi:10.1186/s40942-021-00293-w · Cited by 27
Anders, P., Traber, G. L., Hall, U., Garobbio, S., Chan, E. J., Gabrani, C., Zuche, H. C., Pfau, M., Herzog, M. H., & Scholl, H. P. N. (2023) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.64.14.7 · Cited by 26
“5 13 BCVA and LLVA measure the spatial resolution of the visual system, that is, these tests ask for the smallest detail of high contrast, that can be detected.”
BackgroundXie, X., Corradetti, G., Song, A. E., Pardeshi, A. A., Sultan, W., Lee, J. Y., Yu, F., Zhang, L., Chen, S., Chopra, V., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240110 · Cited by 26
Vision Loss Reduction with Avacincaptad Pegol for Geographic Atrophy
Danzig, C. J., Khanani, A. M., Kaiser, P. K., CHANG, M. A., Kovach, J. L., Lally, D. R., Rachitskaya, A. V., Sheth, V. S., Vajzovic, L. M., Clark, J., et al. (2024) · Ophthalmology Retina · doi:10.1016/j.oret.2024.04.023 · Cited by 26
Silva, T. D., Jayakar, G., Grisso, P., Hotaling, N. A., Chew, E. Y., & Cukras, C. A. (2021) · Ophthalmology Science · doi:10.1016/j.xops.2021.100060 · Cited by 25
Self-citationKaruntu, J. S., Nguyen, X., & Boon, C. J. F. (2023) · Acta Ophthalmologica · doi:10.1111/aos.16601 · Cited by 26
“So treating RP will not likely result in an increased BCVA (Csaky et al., 2017).”
BackgroundKtistakis, E., Simos, P. G., Tsilimbaris, M. K., & Plainis, S. (2023) · Optometry and Vision Science · doi:10.1097/opx.0000000000002064 · Cited by 23
Birner, K., Reiter, G. S., Steiner, I., Deák, G. G., Mohamed, H., Schürer‐Waldheim, S., Gumpinger, M., Bogunović, H., & Schmidt-Erfurth, U. M. (2024) · Scientific Reports · doi:10.1038/s41598-024-72522-9 · Cited by 23
Curcio, C. A., Messinger, J. D., Berlin, A., Sloan, K. R., McLeod, D. S., Edwards, M. M., Bijon, J., & Freund, K. B. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.1.49 · Cited by 24
Birner, K., Reiter, G. S., Steiner, I., Zarghami, A., Sadeghipour, A., Schürer‐Waldheim, S., Gumpinger, M., Bogunović, H., & Schmidt-Erfurth, U. M. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.3.26 · Cited by 23
AI in the clinical management of GA: A novel therapeutic universe requires novel tools
Reiter, G. S., Mai, J., Riedl, S., Birner, K., Frank‐Publig, S., Bogunović, H., & Schmidt-Erfurth, U. M. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101305 · Cited by 24
“The report from the FDA endpoints workshop also supports the use of automated image analysis to gain more reliability and precision (Csaky et al., 2017).”
MethodMaguire, M. G., Birch, D. G., Duncan, J. L., Ayala, A. R., Ayton, L. N., Cheetham, J. K., Cheng, P., Durham, T. A., Ferris, F. L., Hoyng, C. B., et al. (2024) · Translational Vision Science & Technology · doi:10.1167/tvst.13.10.15 · Cited by 23
“Time was calculated as the number of days from baseline divided by 365.25.”
MethodInfluentialSelf-citationKong, X., Ho, A., Muñoz, B. E., West, S. K., Strauss, R. W., Jha, A., Ervin, A., Buzas, J. S., Singh, M. S., Hu, Z. J., et al. (2019) · Translational Vision Science & Technology · doi:10.1167/tvst.8.3.46 · Cited by 23
“The level of intactness of the EZ band is of particular scientific and regulatory interest.(16) However, in this cohort, we observed highly heterogeneous and sporadic partial disruption of the EZ band.”
BackgroundSelf-citationSabeti, F., Lane, J., Rohan, E. M. F., Rai, B. B., Essex, R. W., McKone, E., & Maddess, T. (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.2.10 · Cited by 23
Hwang, C. K., Agrón, E., Domalpally, A., Cukras, C. A., Wong, W. T., Chew, E. Y., & Keenan, T. D. L. (2020) · Ophthalmology Retina · doi:10.1016/j.oret.2020.10.008 · Cited by 22
Self-citationFu, D. J., Glinton, S. L., Lipkova, V., Faes, L., Liefers, B. J., Zhang, G., Pontikos, N., McKeown, A. S., Scheibler, L., Patel, P. J., et al. (2023) · British Journal of Ophthalmology · doi:10.1136/bjo-2022-322672 · Cited by 21
“4 Reporting of GA studies using the CAM-defined OCT endpoints is challenging as such studies require manual segmentation, which is time-consuming, labour-intensive and can feature inter-rater variability.”
BackgroundWu, Z., Cimetta, R., Caruso, E., & Guymer, R. H. (2019) · Translational Vision Science & Technology · doi:10.1167/tvst.8.4.16 · Cited by 21
“In this study, two different test strategies for characterizing deep scotomas were evaluated: (1) a 4-2 staircase thresholding strategy and (2) a defectmapping strategy, which involved single presentations of 10 dB stimuli at each location.”
MethodA Clinical and Preclinical Assessment of Clinical Trials for Dry Age-Related Macular Degeneration
Abidi, M., Karrer, E. E., Csaky, K. G., & Handa, J. T. (2022) · Ophthalmology Science · doi:10.1016/j.xops.2022.100213 · Cited by 19
“According to Clinicaltrials.gov, at the time of the writing of this manuscript, 1871 clinical trials have been conducted on AMD, of which 102 studies have focused on GA.”
BackgroundInfluentialSelf-citationKeenan, T. D. L., Bailey, C., Abraham, M., Orndahl, C. M., Menezes, S. M., Bellur, S., Arunachalam, T., Kangale-Whitney, C., Srinivas, S., Karamat, A., et al. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.0118 · Cited by 19
Self-citationChakravarthy, U., Schwartz, R., Guymer, R. H., Holz, F. G., Rachitskaya, A. V., Vujosevic, S., Lewis, P., Vorwerk, H., Alibhai, A. Y., Moult, E. M., et al. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.02.012 · Cited by 19
Barnes, C. S., Schuchard, R. A., Birch, D. G., Dagnelie, G., Wood, L., Koenekoop, R. K., & Bittner, A. K. (2019) · Translational Vision Science & Technology · doi:10.1167/tvst.8.3.36 · Cited by 19
Duncan, J. L., & Roorda, A. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-27378-1_22 · Cited by 19
Self-citationMethodological Appraisal of Phase 3 Clinical Trials in Geographic Atrophy
Biarnés, M., Garrell-Salat, X., Gómez‐Benlloch, A., Guarro, M., Londoño, G., López, E., Ruiz, S., Vázquez, M., & Sararols, L. (2023) · Biomedicines · doi:10.3390/biomedicines11061548 · Cited by 19
Bennett, C. F., Romano, F., Vingopoulos, F., Garcia, M., Ding, X., Bannerman, A., Ploumi, I., Ntentakis, D. P., Stettler, I., Overbey, K. M., et al. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.11.006 · Cited by 17
Zhao, Y., Lesmes, L. A., Dörr, M., & Lu, Z. (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.12.18 · Cited by 17
Terheyden, J. H., Pondorfer, S. G., Behning, C., Berger, M., Carlton, J., Rowen, D., Bouchet, C., Poor, S. H., Luhmann, U. F. O., Leal, S., et al. (2022) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2021-320848 · Cited by 17
Abraham, J. R., Jaffe, G. J., Kaiser, P. K., Chiu, S. J., Loo, J., Farsiu, S., Bouckaert, L., Karageozian, V. H., Sarayba, M. A., Srivastava, S. K., et al. (2022) · Ophthalmology Retina · doi:10.1016/j.oret.2022.05.002 · Cited by 16
Retinal Imaging Findings in Inherited Retinal Diseases
Corradetti, G., Verma, A., Tojjar, J., Almidani, L., Oncel, D., Emamverdi, M., Bradley, A., Lindenberg, S., Nittala, M. G., & Sadda, S. R. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13072079 · Cited by 16
“…by the FDA, and are thus commonly used in IRD clinical trials, whereas the quantification of photoreceptor loss via optical coherence tomography (OCT) and the measurement of hypo-or hyper-autofluorescent lesions via fundus autofluorescence (FAF) are considered surrogate endpoints [14,17].”
Method
Metadata
- Authors
- Csaky, K., Ferris, F., Chew, E. Y., Nair, P., Cheetham, J. K., & Duncan, J. L.
- Affiliations
- Retina Foundation of the Southwest (US)
- National Institutes of Health (US)
- Washington, District of Columbia, United States
- Foundation Fighting Blindness (US)
- University of California, San Francisco (US)
- Corresponding author
- Duncan, Jacque L.
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2017-07-21
- Volume
- 58
- Issue
- 9
- Pages
- 3456
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- PMC
- PMC5961066
- OpenAlex
- W2735396028
- Cited by
- 231
- References
- 15
- Citations by year
- 2026: 22 · 2025: 38 · 2024: 40 · 2023: 28 · 2022: 26 · 2021: 28 · 2020: 25 · 2019: 15 · 2018: 8 · 2017: 1
- FWCI
- 13.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Keywords
- age-related macular degeneration, inherited retinal disease, clinical trial endpoints, visual function outcomes, retinal degeneration
- MeSH terms
- Clinical Trials as Topic, Humans, Macular Degeneration, Retinal Diseases, Visual Acuity, Visual Fields, Endpoint Determination, Geographic Atrophy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.